drugset / Trial / NCT00915525

Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

NCT00915525 ↗

Phase 3 Completed 829 enrolled Allergan
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the long term safety and effectiveness of botulinum toxin type A in treating patients with idiopathic overactive bladder with urinary incontinence.

Timeline

Start
2010-02-01
Primary completion
2014-08-05
Completion
2014-08-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 100 iu Other
Subject Botulinum toxin type A Protein / enzyme biologic 150 iu Other

Indications